环磷腺苷葡胺对心力衰竭患者NT-proBNP的影响

目的 研究环磷腺苷葡胺对心力衰竭患者的N末端B型脑钠肽前体（NT-proBNP）的影响,评价环磷腺苷葡胺治疗心力衰竭的疗效.方法 112例慢性心力衰竭患者随机分为常规治疗组和环磷腺苷葡胺组各56例,分别测定治疗前及治疗10天后血浆NT-proBNP浓度并进行对比分析.结果 治疗前两组血浆NT-proBNP浓度无明显差异（15479±483） pg/ml vs （15682±395） pg/ml,P＞O.05],治疗后两组血浆NT-proBNP浓度均较治疗前明显降低（6835±542）pg/ml vs（15479±483）pg/ml;（4528±416）pg/ml vs（15682±395）pg/ml,P＜O.05],环磷腺苷葡胺组血浆NT-proBNP的浓度较常规治疗组降低更加明显（4528±416）pg/ml vs（6835±542）pg/ml,P＜0.05）].结论 环磷腺苷葡胺可明显增强心肌收缩力,改善心脏泵血功能,可作为心衰治疗的辅助用药和新选择.

Effect of meglumine adenosine cyclophosphate on N-terminal pro-brain natriuretic peptide in patients with heart failure

Objective To study the effect of meglumine adenosine cyclophosphate （MAC） on N-terminal pro-brain natriuretic peptide （NT-proBNP） in patients with heart failure.Methods 112 patients with chronic heart failure were randomly assigned to conventional therapy group （56 cases） and MAC group （56 cases）.Concentration of plasma NT-proBNP was detected and compared before treatment and after 10 days treatment.Results Concentration of plasma NT-proBNP before treatment between conventional therapy group and MAC group had no significant differences（15479 ± 483） pg/ml vs.（15682±395） pg/ml,P＞0.05）.Concentration of plasma NT-proBNP of each group was significantly lower than that before treatment respectivly（6835 ± 542） pg/ml vs.（15479 ± 483） pg/ml,（4528 ± 416） pg/ml vs.（15682±395） pg/ml,P＜0.05],and the concentration of plasma NT-proBNP of MAC group decreased more significantly than that of conventional therapy group（4528±416） pg/ml vs.（6835±542） pg/ml,P＜0.05].Conclusion Meglumine adenosine eyclophosphate can siginificantly enhance myocardial contractility,improve the blood-pumping function of heart,and can be used as assisting medicine and new choice for treating heart failure.